The Effect of Small Oligomeric Protein Aggregates on the Immunogenicity of Intravenous and Subcutaneous Administered Antibodies

Journal of Pharmaceutical Sciences

Volumn 104, Issue 11, 2015, Pages 3691-3702

  Fathallah, Anas M ^a   Chiang, Manting ^a   Mishra, Anshul ^a   Kumar, Sandeep ^b   Xue, Li ^b   Middaugh, Russell ^c   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

biotechnology; IgG antibody; immune response; particle size; proteins

Indexed keywords

BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; PROTEIN AGGREGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANISOTROPY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOGENICITY; LIGHT SCATTERING; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN UNFOLDING; ANIMAL; ANTIBODY PRODUCTION; CHEMISTRY; DENDRITIC CELL; HUMAN; IMMUNIZATION; IMMUNOLOGY; PROTEIN CONFORMATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; DENDRITIC CELLS; HUMANS; IMMUNIZATION; MICE; PROTEIN AGGREGATES; PROTEIN CONFORMATION; PROTEIN UNFOLDING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944178854     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24592     Document Type: Article

References (35)

1. Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV,. 2012. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci 101 (6): 2055-2065.
2. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W,. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95 (5): 1084-1096.
3. Purohit VS, Middaugh CR, Balasubramanian SV,. 2006. Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice. J Pharm Sci 95 (2): 358-371.
4. Kumar S, Singh SK, Wang X, Rup B, Gill D,. 2011. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res 28 (5): 949-961.
5. Rosenberg AS,. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8 (3): E501-E507.
6. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V,. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287 (30): 25266-25279.
7. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D,. 2012. Classification of protein aggregates. J Pharm Sci 101 (2): 493-498.
8. Guidance for Industry. Immunogenicity assessment for therapeutic protein products. Accessed July 22, 2013, at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf.
9. Fathallah AM, Bankert RB, Balu-Iyer SV,. 2013. Immunogenicity of subcutaneously administered therapeutic proteins-A mechanistic perspective. AAPS J 15: 897-900.
10. Zhong GM, Sousa CRE, Germain RN,. 1997. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med 186 (5): 673-682.
11. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM,. 1995. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 181 (6): 2237-2247.
12. Cumberbatch M, Fielding I, Kimber I,. 1995. Epidermal Langerhans cell migration: Signals and mechanisms. Adv Exp Med Biol 378: 173-175.
13. Rao G, Iyer V, Kosloski MP, Pisal DS, Shin E, Middaugh CR, Balu-Iyer SV,. 2010. Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics. J Pharm Sci 99 (4): 1697-1706.
14. Li Y, Roberts CJ,. 2012. Protein aggregation pathways, kinetics and thermodynamics In Aggregation of therapeutic proteins;, Wang W, Roberts CJ, Eds. Hoboken, New Jersey: John Wiley and Sons Inc.
15. Rosenberg AS, Worobec AS,. 2005. A risk-based approach to immunogenicity concerns for therapeutic protein products. Biopharm Int 18 (1): 32 -36.
16. Frey A, Di Canzio J, Zurakowski D,. 1998. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221 (1-2): 35-41.
17. Bradley JR,. 2008. TNF-mediated inflammatory disease. J Pathol 214 (2): 149-160.
18. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B,. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 (9): 3666-3670.
19. Robak T, Gladalska A, Stepien H,. 1998. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 9 (2): 145-154.
20. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F,. 2000. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1 (4): 311-316.
21. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G,. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 (1): 77-92.
22. Lakowicz JR,. 2006. Principles of fluorescence spectroscopy. New York: Springer.
23. den, Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W,. 2011. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28 (4): 920-933.
24. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C, 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R,. 2011. Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63 (10): 2854-2864.
25. Schiff M,. 2013. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52 (6): 986-997.
26. Davis HL,. 2008. Novel vaccines and adjuvant systems: The utility of animal models for predicting immunogenicity in humans. Hum Vaccin 4 (3): 246-250.
27. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF,. 2012. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol 188 (8): 3724-3733.
28. Wessner DR,. 2010. The origins of viruses. Nat Educ 3 (9): 37.
29. den Dunnen J, Vogelpoel LT, Wypych T, Muller FJ, de Boer L, Kuijpers TW, Zaat SA, Kapsenberg ML, de Jong EC,. 2012. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcgammaRIIa in human dendritic cells. Blood 120 (1): 112-121.
30. Wiseman RL, Powers ET, Kelly JW,. 2005. Partitioning conformational intermediates between competing refolding and aggregation pathways: Insights into transthyretin amyloid disease. Biochemistry 44 (50): 16612-16623.
31. Gage MJ, Robinson AS,. 2003. C-terminal hydrophobic interactions play a critical role in oligomeric assembly of the P22 tailspike trimer. Protein Sci 12 (12): 2732-2747.
32. Robinson CR, Rentzeperis D, Silva JL, Sauer RT,. 1997. Formation of a denatured dimer limits the thermal stability of Arc repressor. J Mol Biol 273 (3): 692-700.
33. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ,. 2012. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm 9 (4): 791-802.
34. Yadav S, Liu J, Shire SJ, Kalonia DS,. 2010. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 99 (3): 1152-1168.
35. Mahler H-C, Jiskoot W,. 2012. Analysis of aggregates and particles in protein pharmaceuticals. Hoboken, New Jersey: John Wiley & Sons Inc.